Mineralys Therapeutics (MLYS) Competitors $11.48 -0.69 (-5.67%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends MLYS vs. IDYA, KROS, NAMS, GERN, AMPH, MIRM, LGND, SUPN, GPCR, and EVOShould you be buying Mineralys Therapeutics stock or one of its competitors? The main competitors of Mineralys Therapeutics include IDEAYA Biosciences (IDYA), Keros Therapeutics (KROS), NewAmsterdam Pharma (NAMS), Geron (GERN), Amphastar Pharmaceuticals (AMPH), Mirum Pharmaceuticals (MIRM), Ligand Pharmaceuticals (LGND), Supernus Pharmaceuticals (SUPN), Structure Therapeutics (GPCR), and Evotec (EVO). These companies are all part of the "pharmaceutical preparations" industry. Mineralys Therapeutics vs. IDEAYA Biosciences Keros Therapeutics NewAmsterdam Pharma Geron Amphastar Pharmaceuticals Mirum Pharmaceuticals Ligand Pharmaceuticals Supernus Pharmaceuticals Structure Therapeutics Evotec IDEAYA Biosciences (NASDAQ:IDYA) and Mineralys Therapeutics (NASDAQ:MLYS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, community ranking, dividends, media sentiment, risk, valuation, profitability and analyst recommendations. Does the media prefer IDYA or MLYS? In the previous week, Mineralys Therapeutics had 10 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 18 mentions for Mineralys Therapeutics and 8 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.13 beat Mineralys Therapeutics' score of -0.09 indicating that IDEAYA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Mineralys Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation and earnings, IDYA or MLYS? Mineralys Therapeutics has lower revenue, but higher earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIDEAYA Biosciences$23.39M98.44-$112.96M-$2.33-11.43Mineralys TherapeuticsN/AN/A-$71.90M-$3.27-3.51 Does the MarketBeat Community favor IDYA or MLYS? IDEAYA Biosciences received 122 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Mineralys Therapeutics an outperform vote while only 70.83% of users gave IDEAYA Biosciences an outperform vote. CompanyUnderperformOutperformIDEAYA BiosciencesOutperform Votes13670.83% Underperform Votes5629.17% Mineralys TherapeuticsOutperform Votes14100.00% Underperform VotesNo Votes Is IDYA or MLYS more profitable? IDEAYA Biosciences' return on equity of -19.42% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets IDEAYA BiosciencesN/A -19.42% -18.63% Mineralys Therapeutics N/A -55.92%-51.70% Do analysts recommend IDYA or MLYS? IDEAYA Biosciences presently has a consensus price target of $53.91, suggesting a potential upside of 102.36%. Mineralys Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 161.32%. Given Mineralys Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Mineralys Therapeutics is more favorable than IDEAYA Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IDEAYA Biosciences 0 Sell rating(s) 2 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.93Mineralys Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, IDYA or MLYS? IDEAYA Biosciences has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500. Do insiders and institutionals hold more shares of IDYA or MLYS? 98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 3.5% of IDEAYA Biosciences shares are held by insiders. Comparatively, 33.2% of Mineralys Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryIDEAYA Biosciences beats Mineralys Therapeutics on 9 of the 17 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get Mineralys Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MLYS vs. The Competition Export to ExcelMetricMineralys TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$571.35M$6.53B$5.15B$8.74BDividend YieldN/A8.16%5.18%4.08%P/E Ratio-3.514.9166.6713.57Price / SalesN/A376.691,276.8487.67Price / CashN/A51.2039.7035.24Price / Book2.419.686.475.93Net Income-$71.90M$154.43M$119.73M$225.73M7 Day Performance-18.23%-9.46%-5.13%-1.34%1 Month Performance-17.29%-7.27%-2.71%1.15%1 Year Performance68.08%28.13%31.08%24.02% Mineralys Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MLYSMineralys Therapeutics3.0672 of 5 stars$11.48-5.7%$30.00+161.3%+71.1%$571.35MN/A-3.5128Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageIDYAIDEAYA Biosciences4.187 of 5 stars$26.71-9.4%N/A-11.0%$2.31B$23.39M-11.4680KROSKeros Therapeutics3.5976 of 5 stars$55.70-7.7%N/A+79.9%$2.26B$150,000.00-10.69100NAMSNewAmsterdam Pharma3.0191 of 5 stars$24.97flatN/A+150.5%$2.25B$14.09M0.0057Short Interest ↑News CoverageHigh Trading VolumeGERNGeron3.5227 of 5 stars$3.69-0.5%N/A+95.7%$2.23B$240,000.00-11.53141AMPHAmphastar Pharmaceuticals4.7981 of 5 stars$44.59-1.0%N/A-20.6%$2.14B$644.40M14.861,761Insider SellingMIRMMirum Pharmaceuticals4.2776 of 5 stars$44.37-4.1%N/A+46.8%$2.13B$264.38M-21.97140Earnings ReportAnalyst ForecastInsider SellingAnalyst RevisionNews CoverageLGNDLigand Pharmaceuticals4.9884 of 5 stars$110.50-4.3%N/A+95.5%$2.09B$131.31M44.0280Analyst ForecastSUPNSupernus Pharmaceuticals2.6821 of 5 stars$35.67-1.4%N/A+27.6%$1.97B$607.52M33.34580Positive NewsGPCRStructure Therapeutics2.1962 of 5 stars$34.31-9.0%N/A-28.7%$1.96BN/A-46.36136Analyst RevisionNews CoverageEVOEvotec1.0293 of 5 stars$5.44+6.7%N/A-44.7%$1.93B$845.74M0.005,061Short Interest ↓News CoverageGap UpHigh Trading Volume Related Companies and Tools Related Companies IDYA Competitors KROS Competitors NAMS Competitors GERN Competitors AMPH Competitors MIRM Competitors LGND Competitors SUPN Competitors GPCR Competitors EVO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MLYS) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mineralys Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MLYS Stock Alerts